STOCK TITAN

Woodbridge (NYSE: TRI) updates 70% Thomson Reuters stake and recent trades

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Thomson Investments Limited, The Woodbridge Company Limited and related Ontario entities filed Amendment No. 24 to update their large ownership position in Thomson Reuters. The group reports beneficial ownership of 312,518,088 common shares, representing 70.56% of the company’s common shares, based on 442,934,310 shares outstanding as of March 31, 2026. Woodbridge alone reports 300,790,959 shares, or 67.91%.

The amendment details recent activity, including a 96,913‑share acquisition under Thomson Reuters’ Amended and Restated Dividend Reinvestment Plan and open‑market sales totaling 200,000 shares on each of March 18, 19 and 20, 2026 by several affiliated investment entities at average prices around $93–94 in the U.S. and C$127–129 in Canada. It also notes a 13,550,000‑share transfer between two Woodbridge affiliates.

The filing states the group plans to maintain its controlling interest but may buy or sell small amounts for liquidity. Woodbridge’s President and CEO, Michael Medline, will stand for election to the Thomson Reuters board at the June 10, 2026 annual meeting. The amendment also discloses directors’ deferred share units, which mirror common share value but lack voting rights, and reaffirms Woodbridge’s obligations under the Thomson Reuters Trust Principles Support Agreement.

Positive

  • None.

Negative

  • None.
Group beneficial ownership 312,518,088 shares (70.56%) Common shares of Thomson Reuters as of March 31, 2026
Woodbridge stake 300,790,959 shares (67.91%) Beneficial ownership of common shares as of March 31, 2026
Shares outstanding 442,934,310 shares Thomson Reuters common shares outstanding as of March 31, 2026
DRIP acquisition 96,913 shares Acquired by 1396164 Ontario Limited on March 10, 2026 under DRIP
Open‑market sales per day 200,000 shares per day Collective sales by Participating Entities on March 18–20, 2026
U.S. sale prices $94.08, $93.24, $92.94 Average prices for U.S. exchange sales on March 18–20, 2026
Internal share transfer 13,550,000 shares Transferred from 1000706525 Ontario Limited to 1908720 Ontario Limited on April 16, 2026
Director DSU holdings 135,916; 17,928; 1,596 DSUs Held by David K. R. Thomson, Peter J. Thomson and Michael Friisdahl as of April 17, 2026
Schedule 13D regulatory
"If the filing person has previously filed a statement on Schedule 13G to report the acquisition…"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
Dividend Reinvestment Plan financial
"acquired 96,913 Common Shares pursuant to the Thomson Reuters Amended and Restated Dividend Reinvestment Plan (the "DRIP")."
A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.
deferred share units financial
"hold 135,916, 17,928 and 1,596 deferred share units ("DSUs"), respectively, issued to them by Thomson Reuters…"
Deferred share units are promises that give an executive or director the right to receive company shares or their cash value at a future date, often when they retire or leave the company. Think of them as a paycheck held in a savings account that converts into stock later; they matter to investors because they tie pay to long-term performance, create potential future dilution of shares, and represent a delayed cash or share obligation the company must eventually fulfill.
Thomson Reuters Trust Principles regulatory
"support the Thomson Reuters Trust Principles (the "Trust Principles") and to exercise its voting rights to give effect…"
controlling interest financial
"Thomson Investments Limited, Woodbridge and the other Reporting Persons plan to maintain their controlling interest in Thomson Reuters."
A controlling interest is when a person or group owns enough shares of a company to influence or make decisions about how it is run. It’s similar to having a majority of votes in a group project, giving you the power to guide decisions. For investors, holding a controlling interest means they can significantly affect the company’s direction and policies.
beneficially owned financial
"beneficially owned by The Woodbridge Company Limited and subsidiaries and 11,727,129 Common Shares beneficially owned by the family…"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.





884903709

(CUSIP Number)
David Colman
65 Queen Street West, Suite 2400, Toronto
Ontario, Z4, M5H 2M8
(416)-364-8700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
04/15/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to rows 8 and 10 above, includes 300,790,959 common shares of Thomson Reuters Corporation ("Common Shares") beneficially owned by The Woodbridge Company Limited and subsidiaries and 11,727,129 Common Shares beneficially owned by the family of the late Roy H. Thomson, the first Lord Thomson of Fleet through various affiliated corporations. In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D


THOMSON INVESTMENTS LIMITED
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
THE WOODBRIDGE COMPANY LIMITED
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
1908720 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
1000706525 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
1396164 Ontario Limited
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
1925124 Ontario Limited
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
Woodbridge Investments Corporation
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
KRT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
DKRT FAMILY CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
DKRT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
DKRT FUNDING CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000920847 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
MB FINANCE CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
TT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
TLT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
TLT ISSUE HOLDCO A CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
TLT ISSUE HOLDCO CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1761173 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
2677295 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000919995 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1754693 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
PJT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000920848 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
PGF INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
PGF FAMILY CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
LCC INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000078931 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000421133 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
LLD INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
2806335 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
JRD INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
2754783 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
GED INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
SEG INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000031857 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
SEG FAMILY CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
TCM INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
DYM INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
BG INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
ACG INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1001404651 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
2808194 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026

FAQ

What is The Woodbridge Company Limited’s direct stake in Thomson Reuters (TRI)?

The Woodbridge Company Limited reports beneficial ownership of 300,790,959 Thomson Reuters common shares, equal to 67.91% of the class. This percentage is also based on 442,934,310 common shares outstanding as of March 31, 2026, and forms the core of the group’s controlling interest.

What recent share transactions by Woodbridge affiliates in Thomson Reuters are disclosed?

Affiliated entities sold 200,000 Thomson Reuters shares on each of March 18, 19 and 20, 2026 in open‑market trades. Those sales were split between U.S. and Canadian exchanges, at average prices around $93–94 in the U.S. and C$127–129 in Canada, plus smaller internal transfers and one DRIP purchase.

How did the Dividend Reinvestment Plan affect Thomson Reuters (TRI) holdings in this filing?

On March 10, 2026, 1396164 Ontario Limited acquired 96,913 Thomson Reuters common shares through the Amended and Restated Dividend Reinvestment Plan. Under such plans, cash dividends are reinvested into additional shares, modestly increasing ownership without open‑market purchases.

What board and governance developments are described for Thomson Reuters (TRI)?

Woodbridge’s President and CEO, Michael Medline, will stand for election to Thomson Reuters’ board at the June 10, 2026 annual meeting. Following his election, he will serve as a Woodbridge representative, reinforcing the controlling shareholder’s direct presence in the company’s boardroom.

What are deferred share units (DSUs) disclosed for Thomson Reuters directors?

As of April 17, 2026, certain Thomson Reuters directors hold DSUs that track the value of one common share each but have no voting rights. DSUs vest on grant, accumulate dividend equivalents, and are settled in common shares or cash only after the director’s board service ends.

What are the Thomson Reuters Trust Principles mentioned in the filing?

The Trust Principles commit Thomson Reuters to preserve integrity, independence, and unbiased news coverage while avoiding control by any single interest. Woodbridge has agreed, via a Trust Principles Support Agreement, to exercise its voting rights in support of these principles as long as it remains family controlled.